257 related articles for article (PubMed ID: 17848677)
21. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.
González-Morales A; Zabaleta A; García-Moure M; Alonso MM; Fernández-Irigoyen J; Santamaría E
J Proteomics; 2019 Mar; 194():168-178. PubMed ID: 30503830
[TBL] [Abstract][Full Text] [Related]
23. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
24. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
Ahmed AU; Thaci B; Tobias AL; Auffinger B; Zhang L; Cheng Y; Kim CK; Yunis C; Han Y; Alexiades NG; Fan X; Aboody KS; Lesniak MS
J Natl Cancer Inst; 2013 Jul; 105(13):968-77. PubMed ID: 23821758
[TBL] [Abstract][Full Text] [Related]
25. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
27. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.
Martinez-Quintanilla J; He D; Wakimoto H; Alemany R; Shah K
Mol Ther; 2015 Jan; 23(1):108-18. PubMed ID: 25352242
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM
Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429
[TBL] [Abstract][Full Text] [Related]
29. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.
Berghauser Pont LM; Balvers RK; Kloezeman JJ; Nowicki MO; van den Bossche W; Kremer A; Wakimoto H; van den Hoogen BG; Leenstra S; Dirven CM; Chiocca EA; Lawler SE; Lamfers ML
Gene Ther; 2015 Dec; 22(12):947-59. PubMed ID: 26196249
[TBL] [Abstract][Full Text] [Related]
30. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.
Martinez-Velez N; Marigil M; García-Moure M; Gonzalez-Huarriz M; Aristu JJ; Ramos-García LI; Tejada S; Díez-Valle R; Patiño-García A; Becher OJ; Gomez-Manzano C; Fueyo J; Alonso MM
Acta Neuropathol Commun; 2019 Apr; 7(1):64. PubMed ID: 31036068
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
[TBL] [Abstract][Full Text] [Related]
32. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo.
Botta G; Passaro C; Libertini S; Abagnale A; Barbato S; Maione AS; Hallden G; Beguinot F; Formisano P; Portella G
Hum Gene Ther; 2012 Jun; 23(6):623-34. PubMed ID: 22475378
[TBL] [Abstract][Full Text] [Related]
34. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
[TBL] [Abstract][Full Text] [Related]
35. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
37. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3.
Kanzawa T; Zhang L; Xiao L; Germano IM; Kondo Y; Kondo S
Oncogene; 2005 Feb; 24(6):980-91. PubMed ID: 15592527
[TBL] [Abstract][Full Text] [Related]
39. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
[TBL] [Abstract][Full Text] [Related]
40. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J
J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
